[ad_1]
The European Medicines Agency (EMA) approved this Friday the vaccination of children between 12 and 15 years with the Pfizer / BioNTech vaccine. Prime Minister I. Šimonytė assured that Lithuania is preparing to make such a decision.
“I think that in the near future, the decisions that would provide an opportunity with those vaccines, on which the agency has made a decision, will also be made in Lithuania. As the decision is recent, it was taken on Friday. (…) We are preparing for that, those opportunities will be given. This will be an opportunity, because the decision to vaccinate children of this age is made by children and guardians, “said I. Šimonytė.
He said it was very important for next fall, when the children would go back to school. He said the children would be vaccinated in June.
“It really could be June,” he said.
Delphi Remember that the EVA announced on Friday that it supports vaccinating children ages 12-15 with Pfizer and BioNTech against a pandemic coronavirus vaccine.
“The EEA Committee for Medicinal Products for Human Use today approved a request to extend the use of the Pfizer-BioNTech vaccine against COVID-19 (Comirnaty) to children aged 12 to 15 years,” the EEA said in a tweet.
Comirnaty is the trade name for the COVID-19 vaccine developed by the American pharmaceutical giant Pfizer and the German research company BioNTech. Pfizer-BioNTech will be the first pandemic coronavirus vaccine approved for adolescents in the community of 27 nations.
Marco Cavaleri, Head of the EEA Vaccine Program, stated that the European Medicines Agency had received all the necessary data to approve the use of the vaccine in adolescents and found that it was effective in protecting against COVID-19. This EEA decision has yet to be approved by the European Commission and national regulators, he added.
Last month, Canada and the United States also allowed the use of this vaccine in adolescents as rich countries approached their vaccination goals for adults and to immunize as many of the population as possible.
It is strictly forbidden to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, it is necessary to cite DELFI as the source.
[ad_2]
